What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Colorectal cancer, Internal medicine, KRAS, Panitumumab and Oncology.
He is interested in Cetuximab, which is a branch of Colorectal cancer.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery.
Salvatore Siena usually deals with KRAS and limits it to topics linked to Oxaliplatin and Fluorouracil.
His research integrates issues of Growth factor receptor and Epidermal growth factor receptor in his study of Panitumumab.
His work deals with themes such as DNA Mutational Analysis, Metastasis, Hazard ratio, Antibody and Survival analysis, which intersect with Oncology.
His most cited work include:
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (4248 citations)
- Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer (2686 citations)
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies (2454 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Oncology, Colorectal cancer, KRAS and Panitumumab.
His Internal medicine research integrates issues from Gastroenterology and Surgery.
Salvatore Siena has researched Oncology in several fields, including Clinical endpoint, Clinical trial, Phases of clinical research, Trastuzumab and Hazard ratio.
His Colorectal cancer research includes themes of Cancer research, Targeted therapy and Epidermal growth factor receptor.
His work carried out in the field of KRAS brings together such families of science as Biomarker and Bioinformatics.
He combines subjects such as Wild type and Oxaliplatin with his study of Panitumumab.
He most often published in these fields:
- Internal medicine (61.13%)
- Oncology (51.71%)
- Colorectal cancer (42.12%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (61.13%)
- Oncology (51.71%)
- Colorectal cancer (42.12%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Colorectal cancer, Cancer research and In patient are his primary areas of study.
His Oncology research incorporates elements of Targeted therapy, Clinical trial, Trastuzumab and Confidence interval.
His studies in KRAS and Cetuximab are all subfields of Colorectal cancer research.
Salvatore Siena has included themes like Exome sequencing and Blockade in his KRAS study.
His research in Cancer research intersects with topics in Cancer cell, Gene, Kinase and DNA mismatch repair.
In his study, which falls under the umbrella issue of Cancer, Stage is strongly linked to Retrospective cohort study.
Between 2018 and 2021, his most popular works were:
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials (196 citations)
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial (114 citations)
- Adaptive mutability of colorectal cancers in response to targeted therapies. (88 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Salvatore Siena mostly deals with Colorectal cancer, Internal medicine, Oncology, Cancer research and Clinical trial.
His Colorectal cancer study deals with the bigger picture of Cancer.
His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine.
His Oncology research includes elements of Lapatinib, Trastuzumab, Young adult, Adverse effect and Confidence interval.
His studies in Cancer research integrate themes in fields like KRAS, Gene and Kinase.
Salvatore Siena interconnects Biomarker, Entrectinib and Central nervous system in the investigation of issues within Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
